The global mergers and acquisitions landscape has entered a markedly more active phase. Within a single 48-hour window, three headline transactions — EDF’s divestiture of its North American energy unit to KKR, Merck KGaA’s $11.3 billion acquisition of Bio-Techne, and ON Semiconductor’s $7 billion all-stock deal for Synaptics — collectively illustrate a structural shift in how strategic and financial buyers are deploying capital. For CFOs, General Counsel, and M&A Directors operating across borders, the signals embedded in these transactions carry direct implications for deal strategy, due diligence frameworks, and regulatory preparedness.

Private Equity and Strategic Buyers Are Competing for Larger, More Defensive Assets

KKR’s acquisition of EDF Power Solutions in the United States and Canada is emblematic of a broader trend: private equity firms are increasingly targeting scaled infrastructure and energy assets that offer predictable cash flows and insulation from macroeconomic volatility. This is not opportunistic deal-making — it reflects a deliberate portfolio construction logic in an environment where interest rate uncertainty persists and traditional growth assets carry elevated risk premiums.

Simultaneously, strategic acquirers are moving with comparable conviction. Merck KGaA’s $11.3 billion purchase of Bio-Techne represents the German science and technology group’s largest transaction in over a decade, signalling that life sciences tools and research-adjacent businesses remain high-conviction consolidation targets. ON Semiconductor’s all-stock acquisition of Synaptics — valued at approximately $7 billion — reinforces that AI-related device exposure is now a strategic imperative in the semiconductor sector, not merely a growth narrative.

The convergence of private equity and corporate acquirers chasing similar asset profiles is compressing deal timelines and elevating valuation benchmarks. For boards and corporate finance teams evaluating either side of a transaction, this competitive dynamic demands sharper pre-deal preparation and a more disciplined approach to post-merger integration planning from the outset.

Cross-Border Complexity Is Increasing — Particularly for European Sellers and Buyers

The EDF-KKR transaction is a textbook example of cross-border deal complexity: a French state-controlled utility divesting North American operations to a US-headquartered private equity firm. Such transactions layer multiple jurisdictional considerations — foreign investment review, energy sector regulation, tax structuring across at least three legal systems, and ESG disclosure obligations that differ materially between European and North American frameworks.

For European sellers engaging North American buyout capital, several structural considerations warrant early attention:

  • CFIUS and equivalent foreign investment screening: Even where a European entity is the seller rather than the buyer, the involvement of state-linked sellers can trigger additional scrutiny in US national security reviews.
  • Warranty and indemnity insurance markets: Cross-border transactions increasingly rely on W&I insurance to bridge valuation gaps and allocate post-closing risk, but policy terms vary significantly by jurisdiction.
  • ESG and sustainability due diligence: European sellers operating under CSRD obligations must ensure that data room disclosures are structured to satisfy both EU regulatory standards and the commercial expectations of US financial buyers.

The Merck KGaA–Bio-Techne deal adds a further dimension: a European strategic acquirer absorbing a US-listed life sciences business will face integration challenges spanning FDA regulatory alignment, US employment law, and the reconciliation of IFRS and US GAAP reporting standards. These are not peripheral concerns — they are central to realising deal value.

Regulatory Scrutiny Is Tightening, Especially in Healthcare and Sensitive Sectors

Beyond federal antitrust review, state-level regulatory intervention is emerging as a material deal risk. Maine’s newly enacted competition legislation introduces additional notice and approval requirements for certain healthcare transactions, with particular implications for private equity-backed consolidation strategies. This follows a broader pattern of sub-federal regulatory activism in the United States that European dealmakers — accustomed to centralised review processes — may underestimate during deal planning.

For transactions involving healthcare assets, digital infrastructure, or businesses with significant consumer data exposure, legal and compliance teams should now build multi-layered regulatory mapping into the earliest stages of due diligence, rather than treating it as a closing-phase exercise.

Implications for Decision-Makers

The current deal environment rewards preparation over speed. Boards and executive teams should consider the following priorities:

  • Revisit portfolio assets through the lens of current private equity appetite — particularly in energy, industrials, and life sciences — to identify potential divestiture opportunities at favourable valuations.
  • Invest in cross-border due diligence infrastructure that addresses regulatory, tax, and ESG dimensions simultaneously, rather than sequentially.
  • Engage post-merger integration planning resources before signing, not after closing. The complexity of transactions like Merck KGaA–Bio-Techne makes early integration design a value-protection imperative.
  • Monitor state and national-level regulatory developments in target markets, particularly in healthcare and technology, as part of ongoing deal screening processes.

Key Takeaway

The acceleration of large-scale, cross-border mergers and acquisitions in the first half of 2025 reflects genuine strategic conviction from both financial and corporate buyers — not merely a cyclical rebound. For European dealmakers, the opportunity is real, but so is the execution complexity. Firms that build rigorous due diligence, regulatory foresight, and post-merger integration discipline into their deal architecture will be best positioned to capture value in this environment.